Tags : Symptoms

Lundbeck Halts P-II Study of Lu AF11167 in Patients with

Shots: The company discontinues P-II proof POC study of Lu AF11167 in patients with schizophrenia, who are experiencing persistent negative symptoms (NCT03793712). The P-II study evaluated two doses of Lu AF11167 vs PBO as monothx. in patients with schizophrenia and persistent prominent negative symptoms The discontinuation is based on the results of a futility interim […]Read More

Cipla Receives FDA’s ANDA Approval for its HFA Inhalation Aerosol

Shots: Cipla’s Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation is first device-based metered dose inhaler receives approval in the US which will further strengthen Cipla’s footprints in the US The first AB-rated generic version of Merck’s Proventil HFA Inhalation Aerosol is targeted to treat acute episodes of bronchospasm or prevention of asthmatic symptoms In end of […]Read More

PRA Health Sciences Launches COVID-19 Monitoring App to Track Symptoms

Shots: PRA Health Science reports the availability of the COVID-19 Monitoring Program, a three-tiered mobile-app driven program tracking the individuals’ physical and psychological symptoms of COVID-19 The app monitors an individual’s COVID-19 status and classifies them into three categories: the educational program, the quarantine program and the in-depth monitoring program The app will allow users […]Read More

Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage

Shots: The US FDA has completed its regulatory review of Oleena software which is a Class II medical device facilitating oncology-related symptoms management and remote patient monitoring Oleena is embedded with clinical algorithms offerings real-time personalized insights and actionable recommendations to the patients for managing their own symptoms while monitoring remote patients will improve clinical […]Read More